ArticleHuman gene therapy methods2017
Scalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines.
Article in Human gene therapy methods, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 106 citations in OpenAlex.
- Suspension-Adapted HEK293FT Cells Enable High-Density Transfection for Efficient Lentiviral Vector Production in CAR-T Therapy.Bioengineering (Basel, Switzerland) · 2026Article
- Uncovering MYOF as a novel therapeutic target in glioblastoma: mechanistic insights and drug discovery.Cell death discovery · 2026Article
- Intensified lentiviral vector perfusion bioprocessing with a spiral inertial microfluidic cell retention device.Lab on a chip · 2026Article
- Lentiviral Vectors: From Wild-Type Viruses to Efficient Multi-Functional Delivery Vectors.International journal of molecular sciences · 2025Review
- Evaluation of Purification Methods for Minimizing Transgene Expression Background During Viral Manufacturing.Human gene therapy · 2025Article
- Perfusion Process Intensification for Lentivirus Production Using a Novel Scale-Down Model.Biotechnology and bioengineering · 2025Article
- Development of Lentiviral Packaging Cells and Scale Up of Production to Meet the Growing Demand in Cell and Gene Therapy.Current gene therapy · 2025Review
- An optimizing lentiviral titer determination assay based on Raji cells.American journal of translational research · 2025Article
- Challenges in lentiviral vector production: retro-transduction of producer cell lines.Frontiers in bioengineering and biotechnology · 2025Article
- Enhancing lentiviral production for WAS gene therapy: a comparative analysis of stable producer cell lines evaluating flatware system and adherent bioreactors in perfusion mode.Frontiers in bioengineering and biotechnology · 2025Article
- Development and validation of a droplet digital PCR method for quantifying lentiviral vector infectious titer.Heliyon · 2024Article
- Establishment and Characterization of a Stable Producer Cell Line Generation Platform for the Manufacturing of Clinical-Grade Lentiviral Vectors.Biomedicines · 2024Article
- Lentiviral vector packaging and producer cell lines yield titers equivalent to the industry-standard four-plasmid process.Molecular therapy. Methods & clinical development · 2024Article
- Updates on CAR T cell therapy in multiple myeloma.Biomarker research · 2024Review
- Production of recombinant vesicular stomatitis virus-based vectors by tangential flow depth filtration.Applied microbiology and biotechnology · 2024Article
- Intensified Influenza Virus Production in Suspension HEK293SF Cell Cultures Operated in Fed-Batch or Perfusion with Continuous Harvest.Vaccines · 2023Article
- Production of retroviral vectors in continuous high cell density culture.Applied microbiology and biotechnology · 2023Article
- Incubation Temperature and Period During Denarase Treatment and Microfiltration Affect the Yield of Recombinant Adenoviral Vectors During Downstream Processing.Molecular biotechnology · 2023Article
- Packaging cells for lentiviral vectors generated using the cumate and coumermycin gene induction systems and nanowell single-cell cloning.Molecular therapy. Methods & clinical development · 2023Article
- Process intensification for lentiviral vector manufacturing using tangential flow depth filtration.Molecular therapy. Methods & clinical development · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lentiviral vectors (LV) represent a key tool for gene and cell therapy applications. The production of these vectors in sufficient quantities for clinical applications remains a hurdle, prompting the field toward developing suspension processes that are conducive to large-scale production. This study describes a LV production strategy using a stable inducible producer cell line. The HEK293 cell line employed grows in suspension, thus offering direct scalability, and produces a green fluorescent protein (GFP)-expressing lentiviral vector in the 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.